PRECIPIO, INC. (NASDAQ:PRPO) Files An 8-K Regulation FD DisclosureItem 7.01
On September6, 2017, Precipio, Inc. (the “Company”) issued a press release, which included a letter to shareholders from the Company’s Chief Executive Officer, Ilan Danieli. As noted in the press release, management will host a business update conference call to discuss recent corporate developments and strategic initiatives on Tuesday, September12, 2017, at 4:30pm Eastern Time. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.
The information in this Current Report on Form8-K furnished under this Item 7.01 shall not be deemed “filed” for any purpose, including for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. Furthermore, the information in this Current Report on Form8-K furnished under this Item 7.01 shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.
| Item 7.01 | Financial Statements and Exhibits. |
Precipio, Inc. ExhibitEX-99.1 2 d425505dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Precipio Provides Shareholder Update Letter NEW HAVEN,…To view the full exhibit click here
About PRECIPIO, INC. (NASDAQ:PRPO)
Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted. PRECIPIO, INC. (NASDAQ:PRPO) Recent Trading Information
PRECIPIO, INC. (NASDAQ:PRPO) closed its last trading session down -0.01 at 2.26 with 35,115 shares trading hands.